Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 2

被引:20
|
作者
Wang, Weisi [1 ]
Lv, Dan [1 ]
Qiu, Ni [2 ]
Zhang, Lei [2 ]
Hu, Chunqi [1 ]
Hu, Yongzhou [1 ]
机构
[1] Zhejiang Univ, Coll Pharmaceut Sci, ZJU ENS Joint Lab Med Chem, Hangzhou 310058, Zhejiang, Peoples R China
[2] Zhejiang Univ, Inst Pharmacol & Toxicol, Coll Pharmaceut Sci, Hangzhou 310058, Zhejiang, Peoples R China
基金
中国国家自然科学基金;
关键词
3,4,5-Trisubstituted aminothiophenes; P53-MDM2; interaction; Anti-cancer; SARs; SMALL-MOLECULE INHIBITORS; P53; PROTEIN; CANCER; POTENT; DOMAIN; GENE;
D O I
10.1016/j.bmc.2013.03.070
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Five series of novel 3,4,5-trisubstituted aminothiophene derivatives and analogs were designed and synthesized based on our previous studies. All target compounds were evaluated for their p53-MDM2 binding inhibitory activities and anti-proliferation activities against A549 and PC3 tumor cell lines. Twelve compounds displayed comparable p53-MDM2 binding inhibitory activities to that of Nutlin-3. Among them, compound 7a exhibited marked binding affinity (IC50 = 0.086 mu M). In addition, most target compounds showed potent anti-proliferation activities with IC50 values at low micromolar level. A good selective profile for wild-type p53 expression cell line was also observed. Molecular docking analysis was performed as well to predict possible binding modes of target compounds with MDM2. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2886 / 2894
页数:9
相关论文
共 50 条
  • [41] A Unique Mdm2-Binding Mode of the 3-Pyrrolin-2-one- and 2-Furanone-Based Antagonists of the p53-Mdm2 Interaction
    Surmiak, Ewa
    Twarda-Clapa, Aleksandra
    Zak, Krzysztof M.
    Musielak, Bogdan
    Tomala, Marcin D.
    Kubica, Katarzyna
    Grudnik, Przemyslaw
    Madej, Mariusz
    Jablonski, Mateusz
    Potempa, Jan
    Kalinowska-Tluscik, Justyna
    Domling, Alexander
    Dubin, Grzegorz
    Holak, Tad A.
    ACS CHEMICAL BIOLOGY, 2016, 11 (12) : 3310 - 3318
  • [42] Design and development of high affinity dual anticancer peptide-inhibitors against p53-MDM2/X interaction
    Rasafar, Nasim
    Barzegar, Abolfazl
    Aghdam, Elnaz Mehdizadeh
    LIFE SCIENCES, 2020, 245
  • [43] Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument
    Furet, Pascal
    Masuya, Keiichi
    Kallen, Joerg
    Stachyra-Valat, Therese
    Ruetz, Stephan
    Guagnano, Vito
    Holzer, Philipp
    Mah, Robert
    Stutz, Stefan
    Vaupel, Andrea
    Chene, Patrick
    Jeay, Sebastien
    Schlapbach, Achim
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (19) : 4837 - 4841
  • [44] Targeting p53-MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials
    Zhu, Haohao
    Gao, Hui
    Ji, Yingying
    Zhou, Qin
    Du, Zhiqiang
    Tian, Lin
    Jiang, Ying
    Yao, Kun
    Zhou, Zhenhe
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [45] Design, synthesis, and biological evaluation of 1,3,5-trisubstituted pyrazoles as tyrosine kinase inhibitors
    Gawandi, Sinthiya J.
    Desai, Vidya G.
    Shingade, Sunil G.
    MEDICINAL CHEMISTRY RESEARCH, 2019, 28 (03) : 267 - 278
  • [46] D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms
    Liu, Min
    Li, Chong
    Pazgier, Marzena
    Li, Changqing
    Mao, Yubin
    Lv, Yifan
    Gu, Bing
    Wei, Gang
    Yuan, Weirong
    Zhan, Changyou
    Lu, Wei-Yue
    Lu, Wuyuan
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (32) : 14321 - 14326
  • [47] Design, Synthesis, Chemical and Biochemical Insights Into Novel Hybrid Spirooxindole-Based p53-MDM2 Inhibitors With Potential Bcl2 Signaling Attenuation
    Aziz, Yasmine M. Abdel
    Lotfy, Gehad
    Said, Mohamed M.
    El Ashry, El Sayed H.
    El Tamany, El Sayed H.
    Soliman, Saied M.
    Abu-Serie, Marwa M.
    Teleb, Mohamed
    Yousuf, Sammer
    Doemling, Alexander
    Domingo, Luis R.
    Barakat, Assem
    FRONTIERS IN CHEMISTRY, 2021, 9
  • [48] Structure-Based Design of Novel Inhibitors of the MDM2-p53 Interaction
    Rew, Yosup
    Sun, Daqing
    De Turiso, Felix Gonzalez-Lopez
    Bartberger, Michael D.
    Beck, Hilary P.
    Canon, Jude
    Chen, Ada
    Chow, David
    Deignan, Jeffrey
    Fox, Brian M.
    Gustin, Darin
    Huang, Xin
    Jiang, Min
    Jiao, Xianyun
    Jin, Lixia
    Kayser, Frank
    Kopecky, David J.
    Li, Yihong
    Lo, Mei-Chu
    Long, Alexander M.
    Michelsen, Klaus
    Oliner, Jonathan D.
    Osgood, Tao
    Ragains, Mark
    Saiki, Anne Y.
    Schneider, Steve
    Toteva, Maria
    Yakowec, Peter
    Yan, Xuelei
    Ye, Qiuping
    Yu, Dongyin
    Zhao, Xiaoning
    Zhou, Jing
    Medina, Julio C.
    Olson, Steven H.
    JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (11) : 4936 - 4954
  • [49] Novel Inhibitors of the MDM2-p53 Interaction Featuring Hydrogen Bond Acceptors as Carboxylic Acid Isosteres
    Gonzalez, Ana Z.
    Li, Zhihong
    Beck, Hilary P.
    Canon, Jude
    Chen, Ada
    Chow, David
    Duquette, Jason
    Eksterowicz, John
    Fox, Brian M.
    Fu, Jiasheng
    Huang, Xin
    Houze, Jonathan
    Jin, Lixia
    Li, Yihong
    Ling, Yun
    Lo, Mei-Chu
    Long, Alexander M.
    McGee, Lawrence R.
    McIntosh, Joel
    Oliner, Jonathan D.
    Osgood, Tao
    Rew, Yosup
    Saiki, Anne Y.
    Shaffer, Paul
    Wortman, Sarah
    Yakowec, Peter
    Yan, Xuelei
    Ye, Qiuping
    Yu, Dongyin
    Zhao, Xiaoning
    Zhou, Jing
    Olson, Steven H.
    Sun, Daqing
    Medina, Julio C.
    JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (07) : 2963 - 2988
  • [50] Meeting Organocatalysis with Drug Discovery: Asymmetric Synthesis of 3,3′-Spirooxindoles Fused with Tetrahydrothiopyrans as Novel p53-MDM2 Inhibitors
    Wang, Shengzheng
    Jiang, Yan
    Wu, Shanchao
    Dong, Guoqiang
    Miao, Zhenyuan
    Zhang, Wannian
    Sheng, Chunquan
    ORGANIC LETTERS, 2016, 18 (05) : 1028 - 1031